The pathology of FXTAS

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In 2002, a syndrome of tremor, ataxia, cognitive decline, and the presence of unique ubiquitin staining intranuclear inclusions in the brain was discovered in premutation males carrying an expansion of between 55 and 200 CGG trinucleotide repeats on the FMR1 gene. This clinical syndrome is now known as fragile X-associated tremor/ataxia (FXTAS) and has been found in both male and female carriers of the expanded premutation allele. The goal of this chapter is to summarize what is known about the anatomical pathology associated with the fragile X premutation and particularly in those individuals with FXTAS. Neuropathology in FXTAS was initially found in the central nervous system, but recent evidence has demonstrated pathological features, including intranuclear inclusions, in the peripheral nervous system, the enteric nervous system, and the neuroendocrine system. The precise cellular dysfunctions that underlie these pathologic features are currently under intense investigation with the goal of prevention and treatment of this devastating disorder.

Original languageEnglish (US)
Title of host publicationFXTAS, FXPOI, and Other Premutation Disorders
PublisherSpringer International Publishing
Pages87-100
Number of pages14
ISBN (Electronic)9783319338989
ISBN (Print)9783319338965
DOIs
StatePublished - Jan 1 2016

Fingerprint

Intranuclear Inclusion Bodies
Neurology
Tremor
Pathology
Ataxia
Enteric Nervous System
Trinucleotide Repeats
Neurosecretory Systems
Peripheral Nervous System
Ubiquitin
Central Nervous System
Alleles
Staining and Labeling
Brain
Genes
Therapeutics
Cognitive Dysfunction
Neuropathology

Keywords

  • Intranuclear inclusions
  • MPC signs
  • Parkinson’s disease
  • RNA toxicity
  • White matter disease

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)

Cite this

Martinez-Cerdeno, V., & Greco, C. (2016). The pathology of FXTAS. In FXTAS, FXPOI, and Other Premutation Disorders (pp. 87-100). Springer International Publishing. https://doi.org/10.1007/978-3-319-33898-9_5

The pathology of FXTAS. / Martinez-Cerdeno, Veronica; Greco, Claudia.

FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, 2016. p. 87-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martinez-Cerdeno, V & Greco, C 2016, The pathology of FXTAS. in FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, pp. 87-100. https://doi.org/10.1007/978-3-319-33898-9_5
Martinez-Cerdeno V, Greco C. The pathology of FXTAS. In FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing. 2016. p. 87-100 https://doi.org/10.1007/978-3-319-33898-9_5
Martinez-Cerdeno, Veronica ; Greco, Claudia. / The pathology of FXTAS. FXTAS, FXPOI, and Other Premutation Disorders. Springer International Publishing, 2016. pp. 87-100
@inbook{572c020c400e487295c2963e490ad825,
title = "The pathology of FXTAS",
abstract = "In 2002, a syndrome of tremor, ataxia, cognitive decline, and the presence of unique ubiquitin staining intranuclear inclusions in the brain was discovered in premutation males carrying an expansion of between 55 and 200 CGG trinucleotide repeats on the FMR1 gene. This clinical syndrome is now known as fragile X-associated tremor/ataxia (FXTAS) and has been found in both male and female carriers of the expanded premutation allele. The goal of this chapter is to summarize what is known about the anatomical pathology associated with the fragile X premutation and particularly in those individuals with FXTAS. Neuropathology in FXTAS was initially found in the central nervous system, but recent evidence has demonstrated pathological features, including intranuclear inclusions, in the peripheral nervous system, the enteric nervous system, and the neuroendocrine system. The precise cellular dysfunctions that underlie these pathologic features are currently under intense investigation with the goal of prevention and treatment of this devastating disorder.",
keywords = "Intranuclear inclusions, MPC signs, Parkinson’s disease, RNA toxicity, White matter disease",
author = "Veronica Martinez-Cerdeno and Claudia Greco",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-33898-9_5",
language = "English (US)",
isbn = "9783319338965",
pages = "87--100",
booktitle = "FXTAS, FXPOI, and Other Premutation Disorders",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - The pathology of FXTAS

AU - Martinez-Cerdeno, Veronica

AU - Greco, Claudia

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In 2002, a syndrome of tremor, ataxia, cognitive decline, and the presence of unique ubiquitin staining intranuclear inclusions in the brain was discovered in premutation males carrying an expansion of between 55 and 200 CGG trinucleotide repeats on the FMR1 gene. This clinical syndrome is now known as fragile X-associated tremor/ataxia (FXTAS) and has been found in both male and female carriers of the expanded premutation allele. The goal of this chapter is to summarize what is known about the anatomical pathology associated with the fragile X premutation and particularly in those individuals with FXTAS. Neuropathology in FXTAS was initially found in the central nervous system, but recent evidence has demonstrated pathological features, including intranuclear inclusions, in the peripheral nervous system, the enteric nervous system, and the neuroendocrine system. The precise cellular dysfunctions that underlie these pathologic features are currently under intense investigation with the goal of prevention and treatment of this devastating disorder.

AB - In 2002, a syndrome of tremor, ataxia, cognitive decline, and the presence of unique ubiquitin staining intranuclear inclusions in the brain was discovered in premutation males carrying an expansion of between 55 and 200 CGG trinucleotide repeats on the FMR1 gene. This clinical syndrome is now known as fragile X-associated tremor/ataxia (FXTAS) and has been found in both male and female carriers of the expanded premutation allele. The goal of this chapter is to summarize what is known about the anatomical pathology associated with the fragile X premutation and particularly in those individuals with FXTAS. Neuropathology in FXTAS was initially found in the central nervous system, but recent evidence has demonstrated pathological features, including intranuclear inclusions, in the peripheral nervous system, the enteric nervous system, and the neuroendocrine system. The precise cellular dysfunctions that underlie these pathologic features are currently under intense investigation with the goal of prevention and treatment of this devastating disorder.

KW - Intranuclear inclusions

KW - MPC signs

KW - Parkinson’s disease

KW - RNA toxicity

KW - White matter disease

UR - http://www.scopus.com/inward/record.url?scp=85018887073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018887073&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-33898-9_5

DO - 10.1007/978-3-319-33898-9_5

M3 - Chapter

AN - SCOPUS:85018887073

SN - 9783319338965

SP - 87

EP - 100

BT - FXTAS, FXPOI, and Other Premutation Disorders

PB - Springer International Publishing

ER -